Chart lookin good, will likely surpass 2011 high of $10 after cancer diagnostics start come to market later this year.
Early details are scarce, with the company disclosing only that it plans to create cloud-based mobile health products and services leveraging big data to “construct a holistic picture of an individual’s health.” The effort will be helmed by Netflix, Netscape, and CAMERON | PACE Group veteran Corey Bridges who became CEO of LifeMap Sciences at the beginning of this year.
“The biggest reason for the scantiness of details is that we’re taking a show don’t tell attitude about this,” Bridges says. But with internal excitement building around the project and with and BioTime’s own reporting requirements as a public company, the team made the decision to pull the curtain back, if only slightly.
Where things get interesting, and a whole lot more credible, however, is when LifeMap announces who it’s recruited to participate. LifeMap today announced a development partnership with The Icahn School of Medicine at Mount Sinai. The effort will be led by world-renowned researcher, Dr. Eric Schadt, founding director of the Icahn Institute for Genomics and Multiscale Biology, who has been named LifeMap’s lead science advisor. Dr. Schadt is highly regarded for his expertise on the “generation and integration of very large-scale sequence variation, molecular profiling, and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology,” the company writes in a statement today.
“We’re not just working remotely with Mt. Sinai, sending a few emails back and forth,” Bridges says. “We will have a team of people working in their facility, cheek to jowl. This is an honest to god co-development partnership.”
Why does BTX need big pharma partner? PanC-DX is a simple blood/urine sample type test, Weill Cornell and OncoCyte might not need a middle man!
Just heard hospital in phili advertising genetic cancer testing on the radio. I think Weill Cornell is a great partner for BTX. Might not need a middle man with OnCoCyes PanC-DX!
Lung cancer obviously harder to detect. Bladder and breast cancer diagnostic test out end of 2015, lung probably 2Q 2016. Also Wagner mentioned other cancer tests in the works.
Thx for the big picture ips, makes me think about how BTX was $30 in 1997 when Wired Magazine hyped their Hextend product and its cryo freezing capabilities. At that time they were a COMPLETELY different company in that they had not yet entered into the stem cell arena. The good news is that unlike 1997 Biotime has like you said built a company on eight years of solid R&D that has opened up new avenues. Who would have thought they would evolve into what looks like a cancer sector powerhouse.
Unlike the Hextend days Biotime is built on a solid foundation of technologies including a worldwide monopoly on the gold standard hESC progenitor ip. If you look at the full chart of BTX you'll notice they were around $30 in 1997 and only a matter of time before they wiz past that high point when we were a shell of a company..
BB, being that you have played BTX for close to a decade, I trust you keep on coming back as you have trust in Dr. west and the empire he has built. What do you think of Cancer diagnostics PanC-DX and do you think OncoCyte will make as successful IPO as AST has been?
Knowing Dr West's biz savvy, he will time a major milestone as we dip over the next days/week.
Both LifeMap and PanC-DX marketing plans to be unveiled soon, IMO, this will take us to the next level of $6-8, and that might be low balling it.
OncoCyte IPO will be great, do you think West would sell right off the bat to big pharma or maybe sell to AST!